anti-CD37 CAR T-cell therapy (CellPoint/Oslo University Hospital/University of Bergen/University of Oslo)

N/A

Report date: 2025/03/14 16:41:34

Base Information

Drug Nameanti-CD37 CAR T-cell therapy (CellPoint/Oslo University Hospital/University of Bergen/University of Oslo)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionLeukocyte antigen CD37 modulators

TargetsLeukocyte antigen CD37

Therapy Area/IndicationsOvarian NeoplasmsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlandsNorway

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOslo Universitetssykehus Hf

China Registration ClassN/A

Develop Information

Active CompaniesOslo Universitetssykehus Hf CellPoint BV University Of Oslo +[4]

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A